This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the potential of AKEEGA (Niraparib and Abiraterone Acetate) from Johnson & Johnson recently approved by the FDA for the treatment of patients with Prostate Cancer
Ticker(s): JNJWho's the expert?
Institution: Methodist Cancer Center
- Radiation oncologist at Methodist Estabrook Cancer Center and Methodist Jennie Edmundson Cancer Center
- Clinical experience using Pylarify among 90 patients
- Believes his role as a physician is to inform, educate and explain and takes into account his patients’ value systems, social situations, overall health and expectations.
Interview Goal Discussing the standard of care and the potential of the First-And-Only Dual Action Tablet, AKEEGA (Niraparib and Abiraterone Acetate) from Johnson & Johnson which was recently approved by the FDA for the treatment of patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer based on the results from the Phase 3 MAGNITUDE clinical study.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
